Oncolytic Viruses (OVs) are novel therapeutics that selectively replicate in and kill tumor cells 
Abstract
Oncolytic Viruses (OVs) are novel therapeutics that selectively replicate in and kill tumor cells 1 . Several clinical trials evaluating the effectiveness of a variety of oncolytic platforms including HSV, Reovirus, and Vaccinia OVs as treatment for cancer are currently underway [2] [3] [4] [5] . One key characteristic of oncolytic viruses is that they can be genetically modified to express reporter transgenes which makes it possible to visualize the infection of tissues by microscopy or bio-luminescence imaging 6, 7 . This offers a unique advantage since it is possible to infect tissues from patients ex vivo prior to therapy in order to ascertain the likelihood of successful oncolytic virotherapy 8 . To this end, it is critical to appropriately sample tissue to compensate for tissue heterogeneity and assess tissue viability, particularly prior to infection 9 . It is also important to follow viral replication using reporter transgenes if expressed by the oncolytic platform as well as by direct titration of tissues following homogenization in order to discriminate between abortive and productive infection. The object of this protocol is to address these issues and herein describes 1. The sampling and preparation of tumor tissue for cell culture 2. The assessment of tissue viability using the metabolic dye alamar blue 3. Ex vivo infection of cultured tissues with vaccinia virus expressing either GFP or firefly luciferase 4. Detection of transgene expression by fluorescence microscopy or using an In Vivo Imaging System (IVIS) 5. Quantification of virus by plaque assay. This comprehensive method presents several advantages including ease of tissue processing, compensation for tissue heterogeneity, control of tissue viability, and discrimination between abortive infection and bone fide viral replication.
Video Link
The video component of this article can be found at http://www.jove.com/video/2854/ Protocol 1. Tissue processing 1 . For best results, this protocol should be performed using freshly isolated tissue deposited in DMEM media containing 10% FBS, 1%
Pennicilin /Streptomycin solution, and 0.1% Amphothericin B solution immediately following surgery prior to processing. If this is not possible, tissues can be left overnight in this medium at 4 degrees prior to processing. 2. Prior to processing the sample, sterilize metal forceps and disposable blades by depositing them in a 70% ethanol solution for at least 5 minutes. Also prepare a 24-well plate with 2 ml of DMEM media containing 10% FBS, 1% Pennicilin /Streptomycin solution, and 0.1% Amphothericin B. 3. Collect the tissue sample in a laminar flow cell culture hood using sterilized forceps and deposit the tissue in an empty 15 cm petri dish, keeping the lid on the side, sterile side up. 4. In the cell culture hood, use a 2 mm biopsy punch to obtain different cores from a variety of regions within the tissue as in Figure 1 . Deposit the cores in the lid of the 15 cm petri with the help of forceps, leaving enough space in between each core so that they can be easily cut along the horizontal axis. 5. Split each core into 4 even quarters using a sterilized razor blade as in Figure 1 . 6. Using a pipet tip, put each core quarter from a given core in a different well from A1 to A4 as in figure 1 , already containing 1.5 ml of DMEM containing 10% FBS, 1% Pennicilin /Streptomycin solution, and 0.1% Amphothericin B solution. Repeat for each core. This should allow representative sampling of the tumor, while minimizing bias in a given well/condition. For better representation, increase the number of cores.
Assessment of tissue viability

Assessing viral titers by plaque assay
1. Prior to quantifying viral titers, tissues must first be homogenized to release viral particles. This can be done several months later in the infected tissue samples are stored at -80 2. Weigh the sample that needs to be homogenized using an analytical scale. In this case, we will use the sample collected from well A2. 3. Place the tissue is in a 5 ml polystyrene round-bottom falcon tube and add 1 ml of PBS. Homogenize the tissue using a tissue homogenizer. If necessary, store the homogenate at -80 for assessment of viral titers at a later time. 4. To titer vaccinia virus, first plate 1 million U2OS cells in a 6-well plate and incubate overnight in a 37 degree, 5% CO 2 humidified incubator such that they have reached approximately 95 % confluency the following day. 5. Use serum free media to do serial dilutions of virus, making sure to change tips between each dilution step. Typically we do 1 in 10 dilutions and use 100 μl to transfer into 900 μl. How many dilutions are made depends on the anticipated virus yield. 6. Following making the dilutions, remove the media covering the plated U20S cells then add 500 μl of diluted virus stock (for each dilution) to infect the U2OS cells. Incubate the cells for 1 hour minutes at 37 degrees Celcius in a 5% CO 2 humidified incubator. 7. During this time, warm up the 2 X concentrated DMEM containing 20% FBS, and the 3% CMC solution in a 37 degree water bath. 8. After the 1 hour incubation, remove the media covering infected U2OS cells. Mix 1:1 volumes of 3% CMC : 2X DMEM, 20% FBS together and use 2 ml of this mixture to cover each well of the infected U2OS cells. 9. Put cells back in a 37 degree 5% CO 2 humidified incubator for another 48 hours. 10. After 48 hours, add 2 ml of methanol-acetic acid fixative on top of the CMC overlay in each well and incubate at room temperature for 10 minutes in a cell culture hood. 11. Discard the fixed overlay and wash remainder off of the wells using tap water. 12. Stain the fixed U2OS cells with 2ml of a coomassie blue solution per well and incubate for 30 minutes at room temperature at low speed on a plate shaker. 13. Remove the coomassie stain from the wells and wash the plates using tap water. Allow to dry with lid off for about an hour. 14. The Resulting viral plaques can be easily visualized in figure 2C . Plates can be stored indefinitely at this stage. 15. Count plaques at the dilution step where between 10 and 100 plaques are visible. 16. Multiply the number of plaques counted by the dilution used and multiply the resulting number by 2 to give a titer in PFU/ml. For example, if 25 plaques are counted in the well where a million-fold dilution was used, the titer of the initial undiluted sample is 25 multiplied by 1 million multiplied by 2 or 50 million PFU/ml. Further divide this number by the weight initially measure for the sample to report titers in PFU/g
Representative Results:
In order to accurately determine whether a surgically obtained normal/tumor tissue sample is or is not infectable with virus, one must first ensure that the tissue sample is at least viable. Fig 1A shows that viability can be assessed using a metabolic dye (Alamar blue) and that both normal and tumor tissue can remain metabolically active over a period of at least 72h. This suggests that tissues cultured ex vivo can support viral replication. A significant advantage of oncolytic viruses is that they can be engineered to express therapeutic or imaging transgenes. Fig 2D-E shows that GFP or Luciferase can be detected from tissues infected ex vivo, further supporting that these tissues are viable and also infectable. Although increased transgene expression is generally associated with viral replication, it does not necessarily equate to a productive viral life cycle that leads to self-amplification and spread, which is thought to be important for therapeutic activity. For this reason, it is necessary to determine whether more virus is produced than what was used to initially infect the tissue. Fig 2B shows that upon viral quantification by plaque assay, more virus is obtained after 72 hours infection then tissue collected immediately after infection. Overall, these data show that surgically excised tumor tissue can remain viable in cell culture for a period of at least 72 hours, during which time viral replication can be supported.
